TUDRIQEV Is Now Available in the U.S. for Advanced Melanoma
Replimune's TUDRIQEV oncolytic immunotherapy is now commercially available in the U.S. for advanced melanoma, moving the platform into real-world clinical pathways.
Topic
Tudriqev
Topic
Topic
Topic
Replimune's TUDRIQEV oncolytic immunotherapy is now commercially available in the U.S. for advanced melanoma, moving the platform into real-world clinical pathways.